Article

Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study

Alzheimer's Research and Therapy (Impact Factor: 3.5). 10/2012; 4(5):43. DOI: 10.1186/alzrt146
Source: PubMed

ABSTRACT INTRODUCTION: Curcumin is a polyphenolic compound derived from the plant Curcuma Long Lin that has been demonstrated to have antioxidant and anti-inflammatory effects as well as effects on reducing beta-amyloid aggregation. It reduces pathology in transgenic models of Alzheimer's disease (AD) and is a promising candidate for treating human AD. The purpose of the current study is to generate tolerability and preliminary clinical and biomarker efficacy data on curcumin in persons with AD. METHODS: We performed a 24-week randomized, double blind, placebo-controlled study of Curcumin C3 Complex with an open-label extension to 48 weeks. Thirty-six persons with mild-to-moderate AD were randomized to receive placebo, 2 grams, or 4 grams/day of oral curcumin for 24 weeks. For weeks 24 through 48, subjects that were receiving curcumin continued with the same dose, while subjects previously receiving placebo were randomized in a 1:1 ratio to 2 or 4 grams/day. The primary outcome measures were incidence of adverse events, changes in clinical laboratory tests and the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) at 24 weeks in those completing the study. Secondary outcome measures included the Neuropsychiatric Inventory (NPI), the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) scale, levels of A1-40 and A1-42 in plasma and levels of A1-42, t-tau, p-tau181 and F2-isoprostanes in cerebrospinal fluid. Plasma levels of curcumin and its metabolites up to 4 hours after drug administration were also measured. RESULTS: Mean age of completers (n = 30) was 73.5 years and mean Mini-Mental Status Examination (MMSE) score was 22.5. One subject withdrew in the placebo (8%, worsened memory), and 5/24 subjects withdrew in the curcumin group (21%, 3 due to gastrointestinal symptoms). Curcumin C3 Complex was associated with lowered hematocrit and increased glucose levels that were clinically insignificant. There were no differences between treatment groups in clinical or biomarker efficacy measures. The levels of native curcumin measured in plasma were low (7.32 ng/mL). CONCLUSIONS: Curcumin was generally well-tolerated though three subjects on curcumin withdrew due to gastrointestinal symptoms. We were unable to demonstrate clinical or biochemical evidence of efficacy of Curcumin C3 Complex in AD in this 24-week placebo-controlled trial though preliminary data suggest limited bioavailability of this compound. Trial registration: ClinicalTrials.gov Identifier: NCT00099710.

Download full-text

Full-text

Available from: Karen Gylys, Nov 19, 2014
1 Follower
 · 
262 Views
  • Source
    • "months patients with mild-to-moderate AD improvements in cognition Rogers et al. 1993 Diclofenac + Misoprostol N/A 25 weeks patients with mild-to-moderate AD no changes in cognition Scharf et al. 1999 Prednisone 20 then 10mg/d 4 weeks then 1 year patients with AD no beneficial changes in cognitive tests Aisen et al. 2000 Hydrochloroquine 200 or 400mg/d 18 months patients with early AD no cognitive/behavioural improvements van Gool et al. 2001 Nimesilude 100mg twice daily 24 weeks patients with probable AD no effect on cognition, clinical status or behaviour Aisen et al. 2002 Rofecoxib 25mg/d 12 months patients with mild-to-moderate AD no delay in cognitive decline Aisen et al. 2003 Naproxen 220mg twice daily 12 months patients with mild-to-moderate AD no delay in cognitive decline Aisen et al. 2003 Rofecoxib 25mg/d 12 months patients with mild-to-moderate AD no improvements in cognition and behaviour Reines et al. 2004 Rofecoxib 25mg/d up to 4 years patients with MCI no improvements in cognition Thal et al. 2005 Celecoxib 200mg twice daily up to 7 years people 70 years or older with family history of AD no improvements in cognitive functions Martin et al. 2008 Naproxen 220mg twice daily up to 7 years people 70 years or older with family history of AD no improvements in cognitive functions Martin et al. 2008 Corticosteroids Estradiol 2mg/d 6 weeks women with senile dementia AD type improvements in cognition and mood in 3/7 women Fillit et al. 1986 Estrogen 1.25mg/d 16 weeks women with mild-to-moderate AD no improvements in cognition or mood Henderson et al. 2000 Curcumin Curcumin 1 or 4g/d 6 months patients with probable AD probable slower decline in cognition Baum et al. 2008 Curcumin C3 Complex 2 or 4g/d 24 weeks patients with mild-to-moderate AD no difference in clinical or biomarker efficacy measures Ringman et al. 2012 Ginkgo biloba EGb 761 240mg/d 24 weeks outpatients with presenile and senile AD better cognition and activities of daily living Kanowski et al. 1997 EGb 761 240mg/d 3 months patients wit mild-to-moderate AD better attention and memory Maurer et al. 1997 EGb 761 120mg/d 52 weeks outpatients with mild to severe AD better cognition and daily living Le Bars et al. 1997 EGb 761 120 or 240mg/d 26 weeks patients with AD no convincing differences in cognition Schneider et al. 2005 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is a progressive neurodegenerative disorder, characterized by deposition of amyloid beta, neurofibrillary tangles, astrogliosis and microgliosis, leading to neuronal dysfunction and loss in the brain. Bio- and histochemical evidence suggests a pivotal role of central and peripheral inflammation in its aetiopathology, linked to the production of free radicals. Numerous epidemiological studies support that the long-term use of non-steroidal anti-inflammatory drugs is preventive against AD, but these medications do not slow down the progression of the disease in already diagnosed patients. There are a number of studies focusing on traditional herbal medicines and small molecules (usually plant secondary metabolites) as potential anti-inflammatory drugs, particulary in respect to cytokine suppression. For instance, ω-3 polyunsaturated fatty acids and a number of polyphenolic phytochemicals have been shown to be effective against inflammation in animal and cell models. Some of these plant secondary metabolites have also been shown to possess antioxidant, anti-inflammatory, anti-amyloidogenic, neuroprotective, and cognition-enhancing effects. This review will overview the the effects of catechins/proanthocyanidins from green tea, curcumin from turmeric, extracts enriched in bacosides from Brahmi, Ginkgo flavone glycosides, and ω-3 polyunsaturated fatty acids not only counteract one pathophysiological aspect of AD in numerous in vitro and in vivo studies of models of AD, but also ameliorate several of the above mentioned pathologies. The evidence suggests that increased consumption of these compounds might lead to a safe strategy to delay the onset of AD. The continuing investigation of the potential of these substances is necessary as they are promising to yield a possible remedy for this pervasive disease.
    CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders) 09/2014; 13(7). DOI:10.2174/1871527313666140917110635 · 2.70 Impact Factor
  • Source
    • "Curcumin has been attributed with neuroprotective potential and the Indo-US Cross National Dementia Study reported that India had a lower incidence and a lower prevalence of Alzheimer's disease (AD) compared to a reference American population (Chandra et al. 1998, 2001). To date, there have been two completed clinical trials investigating the neuroprotective efficacy of curcumin with regard to AD, but both studies have not reported significant neuroprotective effects (Baum et al. 2008; Ringman et al. 2012). One possible explanation for the lack of neuroprotective efficacy may be the low bioavailability of curcumin. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Curcumin from Curcuma longa may exert putative neuroprotective properties in the brain. Impaired mitochondrial function is implicated in Alzheimer's disease and the presence of the apolipoprotein (APO) E4 genotype, which is a risk factor for late-onset Alzheimer's disease, may aggravate mitochondrial malfunction. Here, we report that in the brain of 16-month-old APOE4-targeted replacement mice, adenosine triphosphate (ATP) concentrations were significantly lower than in APOE3 mice. A 3-month dietary supplementation of 0.2 % curcumin numerically increased ATP concentrations in APOE3 and significantly in APOE4 mice compared to the respective controls. Curcumin significantly induced the transcription of peroxisome proliferator-activated receptor (PPAR) γ and mitochondrial transcription factor A (TFAM) in APOE3, but not in APOE4 mice. Moreover, PPARγ coactivator (PGC)-1α and guanine-adenine repeat binding protein α (GABPa) mRNA was only increased in APOE3 mice. Consistent with these observations, protein expression of mitochondrial respiratory complexes, especially of complex IV, also appeared to be increased in APOE3 mice. In conclusion, we provide evidence that curcumin affects mitochondrial function and gene and protein expression in the murine brain despite its low bioavailability and carriers of the Alzheimer's disease-risk genotype APOE4 may be less responsive to dietary curcumin than APOE3 carriers.
    Genes & Nutrition 05/2014; 9(3):397. DOI:10.1007/s12263-014-0397-3 · 3.42 Impact Factor
  • Source
    • "Native curcumin has very low bioavailability [15] and, hence, limited therapeutic efficacy. In many intervention studies, the phytochemical is consequently administered at gram doses [4] [16] [17]. If curcumin indeed impairs iron status, this high-dose supplementation may harbour potential risks that need to be studied in more detail. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Curcumin has been shown to have many potentially health beneficial properties in vitro and in animal models with clinical studies on the toxicity of curcumin reporting no major side effects. However, curcumin may chelate dietary trace elements and could thus potentially exert adverse effects. Here, we investigated the effects of a 6 month dietary supplementation with 0.2% curcumin on iron, zinc, and copper status in C57BL/6J mice. Compared to non-supplemented control mice, we observed a significant reduction in iron, but not zinc and copper stores, in the liver and the spleen, as well as strongly suppressed liver hepcidin and ferritin expression in the curcumin-supplemented mice. The expression of the iron-importing transport proteins divalent metal transporter 1 and transferrin receptor 1 was induced, while hepatic and splenic inflammatory markers were not affected in the curcumin-fed mice. The mRNA expression of other putative target genes of curcumin, including the nuclear factor (erythroid-derived 2)-like 2 and haem oxygenase 1 did not differ between the groups. Most of the published animal trials with curcumin-feeding have not reported adverse effects on iron status or the spleen. However, it is possible that long-term curcumin supplementation and a Western-type diet may aggravate iron deficiency. Therefore, our findings show that further studies are needed to evaluate the effect of curcumin supplementation on iron status.
    02/2014; 2:563-9. DOI:10.1016/j.redox.2014.01.018
Show more